Tanshinone IIA synergistically enhances the antitumor activity of doxorubicin by interfering with the PI3K/AKT/mTOR pathway and inhibition of topoisomerase II: <i>in vitro</i> and molecular docking studies
Aml Ghanem, Hamdy A. Emara, Shaden Muawia, Ahmed I. Abd El Maksoud, Ahmed A. Al‐Karmalawy, Mohamed F. Elshal
Abstract
Schematic diagram showing the pharmacophoric features of doxorubicin and tanshinone IIA as DNA intercalators, and their effects on cardiac tissues.
Topics & Concepts
ChemistryPI3K/AKT/mTOR pathwayTopoisomeraseIn vitroDoxorubicinDocking (animal)Protein kinase BPharmacologyPhosphorylationBiochemistrySignal transductionChemotherapyNursingSurgeryMedicineCancer therapeutics and mechanismsTraditional Chinese Medicine AnalysisCancer Treatment and Pharmacology